OEM Factory for Cas No.94367-42-7 - Prim-O-glucosylcimifugin – Yongjian
OEM Factory for Cas No.94367-42-7 - Prim-O-glucosylcimifugin – Yongjian Detail:
Application of Prim-O-glucosylcimifugin
Prim-o-glucosylcimifugin has potent anti-inflammatory effects. The expression of iNOS and COX-2 can be inhibited by regulating JAK2 / STAT3 signal transduction.
Name of Prim-O-glucosylcimifugin
Chinese name: Cimicifugin glycoside
English Name: (2S)-2-(2-hydroxypropan-2-yl)-4-methoxy-7-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-2,3-dihydrofuro[3,2-g]chromen-5-one
Chinese Alias: Cimicifugin
Bioactivity of Prim-O-glucosylcimifugin
Description:
prim-o-glucosylcimifugin has potent anti-inflammatory effects. The expression of iNOS and COX-2 can be inhibited by regulating JAK2 / STAT3 signal transd
Relevant categories:
Signaling pathway > > immunity and inflammation > > nitric oxide synthase
Research field > > inflammation / immunity
Natural Products > > others
Target: iNOS
COX-2
In Vitro Study:
prim-o-glucosylglycine (POG) is the highest content of chromone and one of the main active components in Fangfeng (RS). Prim-o-glucosylglycine plays an anti-inflammatory role in raw 264.7 macrophages by inhibiting JAK2 / STAT3 signal transduction and inhibiting the expression of iNOS and COX-2. The cytotoxicity of prim-o-glucoside on LPS activated raw 264.7 macrophages was measured. Use LPS (1 μ G / ml) and increasing concentrations of prim-o-glucosylglycine (15, 50 and 100 μ G / ml) for 24 hours, and cell viability was evaluated by CCK-8 assay. Compared with DMSO treated cells (control), 24 hours and exposure to 15-100 μ After g / ml prim-o-glucoside, cell viability was not significantly affected. In order to study the anti-inflammatory effect of prim-o-glucosylglycine, whether prim-o-glucosylglycine can affect NO synthesis was examined in LPS activated raw 264.7 cells. Use LPS (1 μ G / ml) and various concentrations of prim-o-glucosylglycine (15, 50 and 100 μ G / ml) for 24 hours. The concentration was not measured in the culture supernatant by Griess reaction. The concentration of no in the culture supernatant increased significantly with LPS exposure, and prim-o-glucoside significantly inhibited LPS induced no production in a concentration dependent manner [1].
In Vivo Study
bronchoalveolar lavage fluid (BALF) was collected 7 hours after lipopolysaccharide (LPS) administration, and the cytokine level in BALF was measured by ELISA. Compared with the control group, TNF in BALF- α, IL-1 β And IL-6 levels increased significantly. However, pretreatment with prime-o-glucosylglycine (2.5, 5 or 10 mg / kg) significantly down regulated TNF- α, IL-1 β And IL-6 in a dose-dependent manner (P < 0.05, P < 0.05, 0.01) [1].
Cell Experiment
cell counting Kit (CCK-8) was used to determine the cytotoxic concentration of prim-o-glucosylglycine. In short, raw 264.7 cells were treated with 1 per well × The density of 104 cells was inoculated in 96 wells and incubated overnight. Then use 1 μ Cells were stimulated with g / ml LPS and treated with various concentrations of prim-o-glucosylglycine (15, 50 and 100 μ g/ mL; Medchem express, Princeton, NJ, USA) or DMSO treatment. After incubation at 37 ℃ for 24 hours, CCK-8 solution was added to each well and incubated for another hour. Absorbance was measured at 450 nm using a microplate reader [1].
Animal Experiment
mice [1] BALB / C male mice, 8 weeks old, weighing about 18 to 20g. Mice were randomly divided into 5 groups: control group; LPS group; LPS + prime-o-glucosylglycine (2.5, 5 or 10mg / kg body weight). Prime-o-glucosylglycine was administered intraperitoneally. After 1 hour, mice in LPS group and LPS + prime-o-glucosylglycine group were given 50 mg / L intranasal (in) (200 mg / L) μ LLPs to induce acute lung injury. The control mice were given 50% intranasal (in) without LPS μ LPBS
[1]
Reference:
[1]. Zhou J, et al. Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384.
[2]. Chen N, et al. Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2013 Jun;16(2):139-47.
Physicochemical Properties Of Prim-O-glucosylcimifugin
Density: 1.5 ± 0.1 g / cm3
Boiling Point: 736.9 ± 60.0 ° C at 760 mmHg
Molecular Formula: C22H28O11
Molecular Weight: 468.451
Flash Point: 255.0 ± 26.4 ° C
Exact Mass: 468.163147
PSA:168.28000
LogP:-1.35
Steam Pressure: 0.0 ± 2.5 mmHg at 25 ° C
Refractive Index: 1.648
Prim-O-glucosylcimifugin safety information
Safety Statement (Europe): 24 / 25
Customs Code: 29389090
English Alias of Prim-O-glucosylcimifugin
5H-Furo[3,2-g][1]benzopyran-5-one,7-[(β-D-glucopyranosyloxy)methyl]-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-4-methoxy-, (2S)-
HMS2196A10
[(2S)-2-(2-Hydroxypropan-2-yl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside
N1606
[(2S)-2-(2-Hydroxy-2-propanyl)-4-methoxy-5-oxo-2,3-dihydro-5H-furo[3,2-g]chromen-7-yl]methyl β-D-glucopyranoside
Prim-O-glucosylcimifugin
Product detail pictures:
Related Product Guide:
We constantly carry out our spirit of ''Innovation bringing advancement, Highly-quality guaranteeing subsistence, Administration selling advantage, Credit rating attracting buyers for OEM Factory for Cas No.94367-42-7 - Prim-O-glucosylcimifugin – Yongjian , The product will supply to all over the world, such as: Greenland, Argentina, Casablanca, We will supply much better products with diversified designs and professional services. At the same time, welcome OEM, ODM orders, invite friends at home and abroad together common development and achieve win-win, integrity innovation, and expand business opportunities! If you have any question or need more information please feel free to contact us. We are looking forward to receiving your enquiries soon.
By Lulu from Armenia - 2018.12.30 10:21
The after-sale warranty service is timely and thoughtful, encounter problems can be resolved very quickly, we feel reliable and secure.
By Athena from Portugal - 2017.03.28 16:34